CARMELL THERAPEUTICS CORP

Profile

Company Names

CARMELL THERAPEUTICS CORP

Addresses

2403 SIDNEY STREET, SUITE 300, PITTSBURGH, PA 15203

2403 SIDNEY STREET, SUITE 300, PITTSBURGH, PA 15203

3636 BOULEVARD OF THE ALLIES, PITTSBURGH, PA 15213

10 SOUTH TOWER, 320 E. NORTH AVENUE, PITTSBURGH, PA 15212

Phone Numbers

215-688-6196
(412) 508-6519

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2008

State Incorporated:

DELAWARE

Total Amount Raised:

$16,030,342.00

Number of Funding Rounds:

12
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
12
2020-06-24 
$50,000.00 
$50,000.00 
$0.00 
Debt 
11
2019-09-25 
$2,384,324.00 
$3,500,000.00 
$1,115,676.00 
Debt 
10
2018-07-09 
$5,184,535.00 
$7,500,000.00 
$2,315,465.00 
Debt 
9
2017-12-28 
$439,160.00 
$6,000,000.00 
$5,560,840.00 
Equity 
8
2017-09-28 
$1,967,009.00 
$2,000,000.00 
$32,991.00 
Equity 
7
2016-12-28 
$1,055,575.00 
$2,000,000.00 
$944,425.00 
Equity 
6
2016-01-22 
$774,853.00 
$1,000,000.00 
$225,147.00 
Debt 
5
2015-07-24 
$137,233.00 
$300,000.00 
$162,767.00 
Debt 
4
2014-10-27 
$556,172.00 
$556,172.00 
$0.00 
Debt 
3
2013-12-20 
$681,456.00 
$1,000,000.00 
$318,544.00 
Equity 
2
2012-12-14 
$410,797.00 
$500,000.00 
$89,203.00 
Debt 
1
2011-04-11 
$2,389,228.00 
$2,970,000.00 
$580,772.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
DAVID 
W. 
ANDERSON 
DIRECTOR
J. 
MICHAEL 
EGAN 
DIRECTOR
DONNA 
 
GODWARD 
EXECUTIVE OFFICER
RANDOLPH 
 
HUBBELL 
EXECUTIVE OFFICER, DIRECTOR
JAMES 
F. 
JORDAN 
DIRECTOR
STEPHANIE 
 
KLADAKIS 
EXECUTIVE OFFICER
PAUL 
 
KORNBLITH 
DIRECTOR, EXECUTIVE OFFICER
WILLIAM 
 
NEWLIN 
DIRECTOR, EXECUTIVE OFFICER
ALAN 
I. 
WEST 
EXECUTIVE OFFICER, DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D/A
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2019-09-25 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2020-06-24 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2019-09-25 
D/A
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2018-07-09 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2018-07-09 
D/A
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-12-28 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-12-28 
D/A
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-09-28 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2017-09-28 
D/A
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2016-12-28 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2016-12-28 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2016-01-22 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2015-07-24 
D/A
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2014-10-27 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2014-10-27 
D/A
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2013-12-20 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2013-12-20 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Debt 
2012-12-14 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2011-04-11 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
ALERE FINANCIAL PARTNERS
NONE
NONE
DALMORE GROUP, LLC